Wagner, Jessica Kline, C. Leah Zhou, Lanlan Khazak, Vladimir El-Deiry, Wafik Additional file 7: Figure S7. of Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms CD31 expression in HT29 xenografts. Representative IHC staining of CD31 expression from mice treated with indicated drugs. Tumors harvested and placed in paraffin. ONC201: 50 mg/kg every week. Bevacizumab: 5 mg/kg every other week. N=5 tumors, minimum of 3 sections per tumor stained. (PPTX 184 kb) ONC201;Bevacizumab;Cancer therapy 2018-01-22
    https://springernature.figshare.com/articles/presentation/Additional_file_7_Figure_S7_of_Anti-tumor_effects_of_ONC201_in_combination_with_VEGF-inhibitors_significantly_impacts_colorectal_cancer_growth_and_survival_in_vivo_through_complementary_non-overlapping_mechanisms/5812083
10.6084/m9.figshare.5812083.v1